Innovent starts dosing IBI3035 in first-in-human trial against Novo, Lilly insulins
The Phase 1 healthy-volunteer study moved to recruiting, positioning IBI3035 for a glucose-clamp comparison against Insulin Icodec in a receptor class dominated by Novo Nordisk, Eli Lilly and Sanofi.
Executive Summary
- Innovent Biologics moved its Phase 1 trial of IBI3035 from not-yet-recruiting to actively recruiting, with enrollment and timeline held at their original targets.
- The study measures glucose-infusion rate and drug exposure over a week in healthy volunteers against an active insulin comparator, the standard first read on whether an insulin receptor agonist behaves as intended before any diabetes population is dosed.
- IBI3035 enters a target class already populated by marketed and late-stage insulin receptor agonists from Novo Nordisk, Eli Lilly, Sanofi and several Chinese sponsors, so its differentiation will rest on dosing interval and exposure profile rather than being first to test the mechanism.
- The trial's enrollment, timeline and status progression all track within normal bounds for an early-stage program that just opened its clinic, with no protocol instability or completion-date slippage evident.
The status change
Innovent Biologics (Suzhou) Co. Ltd. updated the registry status of its Phase 1 trial for IBI3035 from Not yet recruiting to Recruiting on July 16, 2026, after the study had opened in China on May 8, 2026. The trial enrolls healthy Chinese male adults aged 18 to 45 with normal glucose tolerance and a body-mass index between 19.0 and 24.0 kg/m2, and randomizes them between subcutaneous IBI3035 and an active comparator, Insulin Icodec. The study targets 144 participants and carries a primary completion date of July 30, 2027. NCT07591519+1Clinical Trials of IBI3035 in Healthy SubjectsNCT07591519Clinical Trials of IBI3035 in Healthy SubjectsJul 16, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial measures
The two primary endpoints are the area under the glucose-infusion-rate curve from 0 to 168 hours and the area under the blood drug concentration-time curve over the same window, both standard euglycemic-clamp measures of how an insulin analog lowers blood glucose and how long it stays active in circulation. Secondary endpoints track adverse events, vital signs, 12-lead ECG intervals, anti-drug antibody formation and additional pharmacokinetic parameters including Cmax, Tmax and half-life. As a first-in-human, open-label, randomized comparison in healthy volunteers rather than patients with diabetes, the study is built to characterize exposure and glucose-lowering activity, not to establish clinical efficacy. NCT07591519Clinical Trials of IBI3035 in Healthy SubjectsNCT07591519
Operational trajectory
The enrollment target has not moved since the trial was first posted, holding at 144 with no percentage change recorded, and the primary completion date has not shifted from its original July 30, 2027 date. Innovent's status update followed a routine progression: the study passed clinicaltrials.gov quality control on May 11, 2026, and moved to active recruiting a little over two months later once the first site began enrolling. Across its broader pipeline, Innovent has closed out 100 of 115 completed-or-terminated trials, with 15 terminated, indicating a functioning trial-execution base rather than a program under particular strain. NCT07591519Clinical Trials of IBI3035 in Healthy SubjectsNCT07591519
The competitive field
The insulin receptor agonist class carries more than twenty identified programs sharing the same target, spanning marketed basal and rapid-acting insulins from Novo Nordisk (Insulin Icodec, the trial's own comparator), Eli Lilly (Insulin Lispro-aabc, Insulin Efsitora Alfa) and Sanofi (iGlarLixi), alongside earlier-stage Chinese entrants such as Gan & Lee Pharmaceuticals' GZR4 and GZR33, and Tonghua Dongbao's THDB0206. IBI3035 is not a first-in-class entrant into this mechanism; the class is validated and commercially established, so the trial's competitive value depends on the exposure and duration profile IBI3035 produces relative to the weekly dosing standard Insulin Icodec is setting in Phase 3 testing. Against a field this mature, an insulin receptor agonist earns attention chiefly by matching or extending existing dosing-interval and glucose-control benchmarks in this pharmacokinetic comparison, not by demonstrating that the mechanism works at all.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.